Morgan Rosel Wealth Management, LLC Crispr Therapeutics Ag Transaction History
Morgan Rosel Wealth Management, LLC
- $313 Million
- Q1 2025
A detailed history of Morgan Rosel Wealth Management, LLC transactions in Crispr Therapeutics Ag stock. As of the latest transaction made, Morgan Rosel Wealth Management, LLC holds 20 shares of CRSP stock, worth $1,043. This represents 0.0% of its overall portfolio holdings.
Number of Shares
20Holding current value
$1,043% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding CRSP
# of Institutions
480Shares Held
64.2MCall Options Held
2.15MPut Options Held
1.92M-
Cathie Wood Ark Investment Management LLC | St. Petersburg, Fl10.2MShares$530 Million3.73% of portfolio
-
Capital International Investors Los Angeles, CA6.07MShares$317 Million0.04% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD3.8MShares$198 Million0.09% of portfolio
-
Black Rock Inc. New York, NY2.78MShares$145 Million0.0% of portfolio
-
Nikko Asset Management Americas, Inc.2.54MShares$133 Million1.16% of portfolio
About CRISPR Therapeutics AG
- Ticker CRSP
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 78,009,296
- Market Cap $4.07B
- Description
- CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA....